Literature DB >> 1482291

Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine.

H H Maurer1, T Kraemer.   

Abstract

Selegiline (R(-)-N-methyl-N-(1-phenyl-2-propyl)-2-propinylamine), a selective MAO-B inhibitor used as an antiparkinsonian, is excreted in urine as N-desmethyl selegiline (norselegiline), R(-)-methamphetamine (R(-)-MA), R(-)-amphetamine (R(-)-AM) and their conjugated p-hydroxy derivatives. We found that the fluorescence polarization immunoassays (FPIA) TDx amphetamine/methamphetamine II (AM/MA II) and TDx amphetamine class (AM class) lead to positive results for up to 2 days after a single oral dose of 10 mg selegiline (detection limit: 0.1 mg/l, each). Every urine specimen from long term selegiline patients (10 mg/day) showed positive TDx results during the selegiline regimen. Positive TDx results were confirmed using gas chromatography-mass spectrometry (GC-MS). Selegiline metabolites, particularly MA, could be detected in urine for up to 7 days after intake of a single oral dose of 10 mg selegiline (detection limit: 0.01 mg/l for MA and AM). Norselegiline, the only specific selegiline metabolite, was only detectable for about 12 h. Moreover, norselegiline was not detected in all urine samples from long term selegiline patients (10 mg/day). Since differentiation of selegiline intake from MA/AM abuse by detecting norselegiline was not possible in most cases, an enantioselective GC-MS procedure was developed. It allowed differentiation of the enantiomers of the selegiline metabolites and thereby separation of selegiline intake (only R(-)-enantiomers) from methamphetamine and/or amphetamine abuse (racemates or S(+)-enantiomers). After derivatization with S(-)-N-trifluoroacetyl-prolyl chloride (TPC), the two enantiomers of MA and AM were each separated as diastereomers employing the routinely used achiral GC capillary.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482291     DOI: 10.1007/BF01981508

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors:  G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

2.  Experiences with L-deprenyl in Parkinsonism.

Authors:  E Csanda; J Antal; M Antóny; A Csanaky
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

3.  Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine.

Authors:  H H Maurer; T Kraemer
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

4.  Resolution of methamphetamine stereoisomers in urine drug testing: urinary excretion of R(-)-methamphetamine following use of nasal inhalers.

Authors:  R L Fitzgerald; J M Ramos; S C Bogema; A Poklis
Journal:  J Anal Toxicol       Date:  1988 Sep-Oct       Impact factor: 3.367

  4 in total
  4 in total

Review 1.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine.

Authors:  H H Maurer; T Kraemer
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

Review 3.  Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.

Authors:  Min-Ho Nam; Moonsun Sa; Yeon Ha Ju; Mingu Gordon Park; C Justin Lee
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

4.  Simultaneous Determination of Selegiline, Desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine on Dried Urine Spots by LC/MS/MS: Application to a Pharmacokinetic Study in Urine.

Authors:  Lizhu Chen; Yingjia Yu; Gengli Duan; Xin Wang; Baohua Shen; Ping Xiang
Journal:  Front Chem       Date:  2019-04-17       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.